Medical Condition News

RSS

Erionite in North Dakota roads may increase risk of mesothelioma

As school buses drive down the gravel roads in Dunn County, North Dakota, they stir up more than dirt. The clouds of dust left in their wake contain such high levels of the mineral erionite that those who breathe in the air every day are at an increased risk of developing mesothelioma, a type of cancer of the membranes around the lungs, new research shows.

26 Jul 2011

Type 2 diabetes and obesity in pregnancy is a daunting duo: New research

Type 2 diabetes and obesity in pregnancy is a daunting duo, according to new research published this month in The Journal of Maternal-Fetal and Neonatal Medicine. The study shows that both conditions independently contribute to higher risks, opening the door to a wide range of pregnancy, delivery and newborn complications.

26 Jul 2011

Advaxis submits protocol revision for ADXS-HPV CIN Phase II study

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject "mid strength" dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.

26 Jul 2011

Resolute drug-eluting stent superior to Taxus DES for coronary artery disease

The Resolute drug-eluting stent (DES) from Medtronic, Inc., showed superiority to Boston Scientific Corp.'s Taxus DES on the primary endpoint of the RESOLUTE Japan clinical study: in-stent late lumen loss at eight months.

26 Jul 2011

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc., resubmitted two New Drug Applications to the United States Food and Drug Administration for alogliptin and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.

26 Jul 2011

Diabetes drug rosiglitazone can reduce development of neuropathic pain

The diabetes drug rosiglitazone (Avandia) can control inflammation leading to nerve damage and abnormal pain responses, suggests a paper in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

26 Jul 2011

CRI announces new changes to cancer research funding programs

Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization established in 1953 to advance the science of tumor immunology and foster the discovery of new cancer immunotherapies, announced today new changes and additions to its research funding programs.

26 Jul 2011

Researchers identify elusive gene responsible for Grey Platelet Syndrome

Researchers have identified an elusive gene responsible for Grey Platelet Syndrome, an extremely rare blood disorder in which only about 50 known cases have been reported. As a result, it is hoped that future cases will be easier to diagnose with a DNA test.

26 Jul 2011

Phadia demonstrates ImmunoCAP Molecular Allergy testing at AACC 2011

Today, at the 2011 American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo, Phadia, the global leader in allergy and autoimmune disease-related diagnostics, demonstrates how ImmunoCAP Molecular Allergy can help improve the diagnosis and management of food allergy.

26 Jul 2011

Drugs targeting specific brain region could help people with schizophrenia manage daily life, study shows

A new study has identified the neural mechanism that hinders reward identification and decision-making in people suffering from schizophrenia, highlighting the need for more effective drug therapies to help people with the disease manage their daily lives.

25 Jul 2011

Fragile X syndrome study to reveal more

Fragile X syndrome is the most common inherited cause of intellectual disability in the world. Medical experts, including the Mater Hospital's Dr Helen Heussler, are today launching a new push to uncover the secrets of a disorder that affects a child born in Australia every week. Fragile X is passed from parent carriers who often exhibit very few symptoms. Estimates suggest more than 100,000 Australians either carry the gene mutation that causes Fragile X or have the syndrome, yet the vast majority have not been diagnosed, according to the Fragile X Association of Australia.

25 Jul 2011

Promising drug for Duchenne muscular dystrophy

Duchenne muscular dystrophy is a severely debilitating and lethal condition that affects 1 in 3,000. Females and males are affected, though females are rarely affected and are more often carriers. It is caused due to a defective gene that normally codes for the protein dystrophin, which helps provide a protective membrane around muscle fibers. Without this skin, muscle fibers become damaged and eventually die.

25 Jul 2011

When psoriasis strikes the famously beautiful

It appears that psoriasis spares none. Reality TV star Kim Kardashian has been reportedly diagnosed with the skin condition. Her condition was revealed on a recent episode of “Keeping Up with the Kardashians” on E!.

25 Jul 2011

Affordable cell transfer therapy for cancers

One of the latest attempts to boost the body's defenses against cancer is called adoptive cell transfer, in which patients receive a therapeutic injection of their own immune cells. This therapy, currently tested in early clinical trials for melanoma and neuroblastoma, has its limitations: Removing immune cells from a patient and growing them outside the body for future re-injection is extremely expensive and not always technically feasible.

25 Jul 2011

Enrollment commences in Lutonix LEVANT 2 drug-coated balloon IDE trial for PAD

Lutonix today announced the first patient enrolled in the LEVANT 2 clinical trial, a global, multicenter, randomized trial evaluating the safety and efficacy of the Moxy™ Drug Coated Balloon compared to a standard angioplasty balloon for the treatment of peripheral arterial disease (PAD). The first case was performed at St. John's Hospital in Springfield, IL by Dr. Jeff Goldstein.

25 Jul 2011

Genesis Biopharma partners with Lonza for Contego to treat metastatic melanoma

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, and Lonza, today announced the signing of a process development and scale-up agreement relating to the manufacture of Contego™, Genesis Biopharma's autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma.

25 Jul 2011

Waters receives CE mark for MassTrak Immunosuppressants XE Kit

Waters Corporation (NYSE: WAT) today announced that its MassTrak™ Immunosuppressants XE Kit is now CE-marked in accordance with the IVD Directive 98/79/EC, for the quantitative measurement of the immunosuppressive drugs tacrolimus in liver and kidney transplant patients and everolimus in adult kidney and cardiac transplant patients from human whole blood samples as an aid in the management of immunosuppressant drug therapy.

25 Jul 2011

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Threshold Pharmaceuticals, Inc., today announced that the University of Texas at San Antonio initiated a clinical trial of TH-302 in combination with bevacizumab in patients with recurrent high grade astrocytoma including glioblastoma.

25 Jul 2011

Ranbaxy announces launch of Letrozole Tablets in UK, Romania and France

Ranbaxy Laboratories Limited today announced the launch of Letrozole Tablets 2.5 mg in UK, Romania and France, on Day-1. Letrozole is the bio equivalent of Femara, the innovator product of Novartis, that has a market size of USD 58 Mn in UK, USD 95 Mn in France and USD 5.5 Mn in Romania.

25 Jul 2011

Australian TGA approves GI Dynamics EndoBarrier Gastrointestinal Liner for type 2 diabetes and obesity

GI Dynamics, Inc., a company focused on the development and commercialization of effective, non-surgical approaches for the treatment of type 2 diabetes and obesity, today announced that the Australian Therapeutic Goods Administration (TGA) has approved the EndoBarrier® Gastrointestinal Liner for inclusion on the Australian Register of Therapeutic Goods (ARTG).

25 Jul 2011